scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Gregory Prince | Q5607119 |
Jorge C Blanco | Q55193786 | ||
Stefanie N. Vogel | Q92126561 | ||
Kari Ann Shirey | Q115088605 | ||
Marina Boukhvalova | Q123569133 | ||
P2860 | cites work | Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience | Q45741859 |
Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). | Q45746077 | ||
Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden | Q45752482 | ||
Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection | Q45752590 | ||
A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology | Q45754571 | ||
Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia | Q45757916 | ||
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus | Q45759631 | ||
Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response | Q45761593 | ||
A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine | Q45773865 | ||
Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls | Q45786507 | ||
Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population | Q45823296 | ||
Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine | Q45823297 | ||
Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. | Q45828600 | ||
Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen | Q45831199 | ||
An outbreak of respiratory syncytial virus in a bone marrow transplant center | Q45866494 | ||
Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children | Q45888997 | ||
Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge | Q47435138 | ||
TLR4 agonists as immunomodulatory agents | Q50076068 | ||
Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. | Q50213048 | ||
Bronchiolitis-associated hospitalizations among US children, 1980-1996. | Q50653027 | ||
IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. | Q51889027 | ||
CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. | Q52525157 | ||
Comparison of cytokine responses in nasopharyngeal aspirates from children with viral lower respiratory tract infections. | Q53051358 | ||
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines | Q56689869 | ||
Experimental RS virus infection of cotton rats. A viral and immunofluorescent study | Q70657671 | ||
Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group | Q71958863 | ||
Requirement for STAT1 in LPS-induced gene expression in macrophages | Q73778456 | ||
MD-2 binds to bacterial lipopolysaccharide | Q74355716 | ||
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group | Q77300551 | ||
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4 | Q22009943 | ||
TLR4 mutations are associated with endotoxin hyporesponsiveness in humans | Q22254186 | ||
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene | Q22299417 | ||
Genetic and Physical Mapping of theLpsLocus: Identification of the Toll-4 Receptor as a Candidate Gene in the Critical Region | Q22337434 | ||
Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran | Q24292781 | ||
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex | Q24316449 | ||
Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice | Q24329114 | ||
Toll-like receptor signalling | Q24570126 | ||
Activation of innate immune antiviral responses by Nod2 | Q24646833 | ||
Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma | Q24791881 | ||
Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function | Q27486621 | ||
Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa | Q27645881 | ||
Alternative activation of macrophages | Q27860939 | ||
Toll-like receptors: critical proteins linking innate and acquired immunity | Q29615190 | ||
CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression | Q31725312 | ||
Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P. | Q33302897 | ||
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion | Q33545548 | ||
Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. | Q33737766 | ||
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant | Q33738521 | ||
Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines | Q33753562 | ||
RSV fusion (F) protein DNA vaccine provides partial protection against viral infection | Q33775390 | ||
Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge | Q33783066 | ||
Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus | Q33848810 | ||
Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate | Q33895116 | ||
Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model | Q33901537 | ||
Respiratory syncytial virus infection in adults | Q33961877 | ||
Respiratory syncytial virus infection in inbred mice | Q34098698 | ||
DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys | Q43444618 | ||
A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine | Q43534761 | ||
Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus | Q43852460 | ||
Interleukin-4 and interleukin-13 signaling connections maps | Q44469051 | ||
Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA. | Q45106083 | ||
Antibody affinity maturation and respiratory syncytial virus disease | Q45383013 | ||
Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells. | Q45401032 | ||
Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses | Q45406272 | ||
The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. | Q45417025 | ||
Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncitial virus bronchiolitis | Q45418783 | ||
Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy. | Q45495234 | ||
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants | Q45504141 | ||
Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease | Q45640302 | ||
The role of Toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virus | Q45658652 | ||
Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis | Q45723418 | ||
Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis | Q45723625 | ||
Association of cytokine responses with disease severity in infants with respiratory syncytial virus infection | Q45730272 | ||
Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways | Q45730326 | ||
The role of IFN in respiratory syncytial virus pathogenesis | Q45733409 | ||
Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine | Q45734744 | ||
Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis | Q45736349 | ||
Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity | Q45736571 | ||
Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease | Q45738401 | ||
Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. | Q45739727 | ||
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus | Q45739890 | ||
Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity | Q45740483 | ||
Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice | Q45740485 | ||
DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation | Q45740607 | ||
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant | Q34226850 | ||
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease | Q34330690 | ||
Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. | Q35552804 | ||
Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children | Q35562475 | ||
Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection | Q35582849 | ||
IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse | Q35665094 | ||
TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression | Q35679602 | ||
Respiratory syncytial virus-induced immunoprotection and immunopathology | Q35882894 | ||
The pathogenesis of respiratory syncytial virus infection in cotton rats | Q36058867 | ||
Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4) | Q36367812 | ||
A role for immune complexes in enhanced respiratory syncytial virus disease | Q36371267 | ||
Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. | Q36400958 | ||
Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus | Q36401291 | ||
Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by ant | Q36691093 | ||
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus | Q36858777 | ||
Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats | Q36903965 | ||
Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. | Q37051620 | ||
Mechanisms of immunity to respiratory syncytial virus in cotton rats | Q37103582 | ||
Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations | Q37356770 | ||
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity | Q37401975 | ||
Challenges in developing a pediatric RSV vaccine | Q37531753 | ||
Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus | Q37579808 | ||
Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. | Q38359641 | ||
Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children | Q38430750 | ||
Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats | Q39585262 | ||
Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays | Q39604025 | ||
Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells | Q40208138 | ||
Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling | Q40265496 | ||
Role for innate IFNs in determining respiratory syncytial virus immunopathology | Q40419767 | ||
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy | Q40614352 | ||
Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent | Q40734229 | ||
TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. | Q40744508 | ||
Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus | Q40780003 | ||
Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells | Q40928270 | ||
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine | Q40940832 | ||
A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3. | Q42068164 | ||
Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. | Q42428474 | ||
Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus | Q42723106 | ||
P433 | issue | 6 | |
P921 | main subject | vaccine | Q134808 |
P304 | page(s) | 482-492 | |
P577 | publication date | 2010-06-01 | |
P1433 | published in | Hum Vaccin | Q15755183 |
P1476 | title | New insights for development of a safe and protective RSV vaccine | |
P478 | volume | 6 |
Q37368692 | A Minimum Epitope Overlap between Infections Strongly Narrows the Emerging T Cell Repertoire. |
Q34401644 | A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation |
Q38733975 | Advances in Antiviral Therapies Targeting Toll-like Receptors |
Q38130514 | Advances in and the potential of vaccines for respiratory syncytial virus |
Q34484085 | Agents that increase AAM differentiation blunt RSV-mediated lung pathology |
Q41721418 | An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization |
Q47562812 | Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts |
Q39393694 | Burden of respiratory syncytial virus infection in young children |
Q36977881 | Cell-mediated immune responses to respiratory syncytial virus infection: magnitude, kinetics, and correlates with morbidity and age |
Q35615024 | Contributions of humoral and cellular immunity to vaccine-induced protection in humans. |
Q38919640 | CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells i |
Q33881536 | Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection |
Q47553316 | Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field |
Q35488618 | Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection |
Q28486995 | Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus |
Q26822938 | Human Metapneumovirus: lessons learned over the first decade |
Q33887642 | Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model |
Q38068065 | Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy |
Q35690781 | Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract |
Q33751615 | Natural killer T cell sensitization during neonatal respiratory syncytial virus infection induces eosinophilic lung disease in re-infected adult mice |
Q37086092 | Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice |
Q40702974 | Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells |
Q34999938 | Novel drugs targeting Toll-like receptors for antiviral therapy |
Q34796481 | Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity |
Q37945230 | Pattern recognition receptors and the innate immune response to viral infection |
Q38018768 | Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines |
Q38206841 | Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective. |
Q37841269 | Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention |
Q35887649 | Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination |
Q36464016 | Proteomic contributions to our understanding of vaccine and immune responses |
Q45364295 | RSV 2010: Recent advances in research on respiratory syncytial virus and other pneumoviruses |
Q34506016 | Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats |
Q39719279 | Respiratory syncytial virus prevention in children with congenital heart disease: who and how? |
Q56893551 | Respiratory syncytial virus vaccine development |
Q38079432 | Respiratory syncytial virus: current progress in vaccine development |
Q38508568 | Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology. |
Q43625547 | Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine |
Q40408421 | Selective evolution of Toll-like receptors 3, 7, 8, and 9 in bats |
Q37328584 | Targeting RSV with vaccines and small molecule drugs |
Q43788138 | The cotton rat (Sigmodon hispidus) as an animal model for respiratory tract infections with human pathogens |
Q40933366 | The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis. |
Q38167718 | Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous |
Q64102227 | Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine |
Q61804920 | Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus |
Search more.